Abeona Therapeutics
ABEO
99 hedge funds and large institutions have $232M invested in Abeona Therapeutics in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 22 increasing their positions, 33 reducing their positions, and 24 closing their positions.
51% more call options, than puts
Call options by funds: $1.59M | Put options by funds: $1.05M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.59% less ownership
Funds ownership: 72.52% → 67.93% (-4.6%)
5% less funds holding
Funds holding: 104 → 99 (-5)
13% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 24
33% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 33
48% less capital invested
Capital invested by funds: $444M → $232M (-$212M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.84M |
| 2 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$5.66M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.45M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.93M |
| 5 |
Millennium Management
New York
|
+$2.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$14.2M |
| 2 |
NC
Nexthera Capital
New York
|
-$10.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.56M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.06M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$4.21M |
ABEO Hedge Fund Activity: Q4 2018 in Review
99 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q4 2018, worth a combined $232M — down 48% from $444M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ABEO and 21 opened new positions — a net loss of 3 holders — while 33 trimmed existing stakes and 22 added.
The largest buyer was Wellington Management Group, adding an estimated $6.84M. The largest seller was State Street, cutting an estimated $14.2M.
- 99 institutional investors held Abeona Therapeutics (ABEO) as of Q4 2018, down from 104 in Q3 2018.
- Funds reported $232M of Abeona Therapeutics stock for Q4 2018, down 48% quarter-over-quarter.
- 21 funds opened new Abeona Therapeutics positions in Q4 2018 and 24 closed out, a net change of -3 holders.
- The largest Abeona Therapeutics buyer in Q4 2018 was Wellington Management Group, an estimated $6.84M added.
- The largest Abeona Therapeutics seller in Q4 2018 was State Street, an estimated $14.2M sold.
Based on aggregated 13F filings for Q4 2018.